Cost-effectiveness analyses of denosumab for osteoporosis: a systematic review

德诺苏马布 医学 特立帕肽 骨质疏松症 雷奈酸锶 雷洛昔芬 指南 系统回顾 内科学 物理疗法 梅德林 骨矿物 乳腺癌 癌症 法学 病理 雌激素受体 政治学
作者
Yi Wan,Fang Zeng,Haoyu Tan,Yanjiao Lu,Yonghui Zhang,Liheng Zhao,Ruxu You
出处
期刊:Osteoporosis International [Springer Nature]
卷期号:33 (5): 979-1015 被引量:12
标识
DOI:10.1007/s00198-021-06268-9
摘要

This paper systematically reviewed and assessed all retrievable pharmacoeconomic studies on denosumab for the treatment of osteoporosis. Denosumab was more cost-effective in patients with older age, prior fracture experience, lower BMD T-scores, and more risk factors. ESCEO-IOF guidelines were more applicable to improve the quality of pharmacoeconomic studies in osteoporosis.There are many pharmacoeconomic studies on denosumab for osteoporosis. However, the corresponding reviews are outdated or incomplete and need to be updated and refined. This article aims to systematically review and evaluate all retrievable pharmacoeconomic studies of denosumab for osteoporosis.A systematic literature search was performed utilizing PubMed, EMBASE(Ovid), Proquest(EconLit), Chongqing VIP, WanFang Database, and Chinese National Knowledge Infrastructure to identify full-text articles published before September 2021. The quality of full-text articles was evaluated by the Consolidated Health Economic Evaluation Reporting Standards(CHEERS) and the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases International Osteoporosis Foundation guideline(ESCEO-IOF).In total, 21 full-text articles were eligible for inclusion. Denosumab for postmenopausal osteoporosis was not dominant compared to zoledronate and teriparatide. However, denosumab was dominant compared with strontium ranelate, raloxifene, and ibandronate in patients over 65 years. The probabilities of denosumab being cost-effective or dominant were more than 85% compared with no treatment and risedronate in patients aged over 70 years. Compared to alendronate, the highest rate of denosumab dominance occurred in patients aged 65 to 75 years, at about 65%. Most of the articles had higher CHEERS scores than ESCEO-IOF scores (converted into percentages).The cost-effectiveness of denosumab for the treatment of osteoporosis was influenced by multiple factors. Generally, denosumab was more cost-effective in patients with older age, prior fracture experience, lower BMD T-scores, and more risk factors. ESCEO-IOF guidelines were more applicable to improve the transparency, generalization, and quality of pharmacoeconomic studies in osteoporosis.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
Carrots完成签到 ,获得积分20
1秒前
开心发布了新的文献求助10
1秒前
spirit发布了新的文献求助10
3秒前
独立江湖女完成签到 ,获得积分10
3秒前
精明书桃完成签到 ,获得积分10
8秒前
小小土豆片完成签到,获得积分10
10秒前
科目三应助QYW采纳,获得10
10秒前
橙子味的邱憨憨完成签到 ,获得积分10
12秒前
苗玉完成签到,获得积分10
13秒前
看文献完成签到,获得积分10
15秒前
16秒前
iu完成签到,获得积分10
17秒前
深情的友易完成签到,获得积分10
17秒前
18秒前
科科发布了新的文献求助100
18秒前
Zzz完成签到 ,获得积分10
19秒前
香蕉觅云应助xxx采纳,获得10
20秒前
博弈春秋发布了新的文献求助10
22秒前
领导范儿应助科研通管家采纳,获得10
22秒前
wanci应助科研通管家采纳,获得10
23秒前
深情安青应助科研通管家采纳,获得10
23秒前
CipherSage应助科研通管家采纳,获得10
23秒前
刘维尼完成签到,获得积分20
23秒前
脑洞疼应助科研通管家采纳,获得10
23秒前
小二郎应助科研通管家采纳,获得10
23秒前
bkagyin应助科研通管家采纳,获得10
23秒前
Owen应助科研通管家采纳,获得10
23秒前
所所应助科研通管家采纳,获得10
23秒前
小蘑菇应助科研通管家采纳,获得10
23秒前
24秒前
在水一方应助科研通管家采纳,获得10
24秒前
CodeCraft应助科研通管家采纳,获得10
24秒前
lixiao应助科研通管家采纳,获得10
24秒前
Lucas应助科研通管家采纳,获得10
24秒前
所所应助科研通管家采纳,获得10
24秒前
24秒前
24秒前
24秒前
Zozo完成签到,获得积分10
24秒前
激情的一斩完成签到,获得积分10
25秒前
高分求助中
Sustainability in Tides Chemistry 2800
Kinetics of the Esterification Between 2-[(4-hydroxybutoxy)carbonyl] Benzoic Acid with 1,4-Butanediol: Tetrabutyl Orthotitanate as Catalyst 1000
The Young builders of New china : the visit of the delegation of the WFDY to the Chinese People's Republic 1000
Rechtsphilosophie 1000
Bayesian Models of Cognition:Reverse Engineering the Mind 888
Handbook of Qualitative Cross-Cultural Research Methods 600
Very-high-order BVD Schemes Using β-variable THINC Method 568
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3137423
求助须知:如何正确求助?哪些是违规求助? 2788470
关于积分的说明 7786719
捐赠科研通 2444666
什么是DOI,文献DOI怎么找? 1300018
科研通“疑难数据库(出版商)”最低求助积分说明 625731
版权声明 601023